WO2009011889A3 - Compounds and methods for treatment of sickle cell disease or complications associated therewith - Google Patents

Compounds and methods for treatment of sickle cell disease or complications associated therewith Download PDF

Info

Publication number
WO2009011889A3
WO2009011889A3 PCT/US2008/008745 US2008008745W WO2009011889A3 WO 2009011889 A3 WO2009011889 A3 WO 2009011889A3 US 2008008745 W US2008008745 W US 2008008745W WO 2009011889 A3 WO2009011889 A3 WO 2009011889A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compounds
methods
associated therewith
sickle cell
Prior art date
Application number
PCT/US2008/008745
Other languages
French (fr)
Other versions
WO2009011889A4 (en
WO2009011889A2 (en
Inventor
John L Magnani
Original Assignee
Glycomimetics Inc
John L Magnani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc, John L Magnani filed Critical Glycomimetics Inc
Priority to EP08794556A priority Critical patent/EP2173351A2/en
Priority to CA2693590A priority patent/CA2693590A1/en
Publication of WO2009011889A2 publication Critical patent/WO2009011889A2/en
Publication of WO2009011889A3 publication Critical patent/WO2009011889A3/en
Publication of WO2009011889A4 publication Critical patent/WO2009011889A4/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Abstract

Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
PCT/US2008/008745 2007-07-18 2008-07-16 Compounds and methods for treatment of sickle cell disease or complications associated therewith WO2009011889A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08794556A EP2173351A2 (en) 2007-07-18 2008-07-16 Compounds and methods for treatment of sickle cell disease or complications associated therewith
CA2693590A CA2693590A1 (en) 2007-07-18 2008-07-16 Compounds and methods for treatment of sickle cell disease or complications associated therewith

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95998407P 2007-07-18 2007-07-18
US60/959,984 2007-07-18

Publications (3)

Publication Number Publication Date
WO2009011889A2 WO2009011889A2 (en) 2009-01-22
WO2009011889A3 true WO2009011889A3 (en) 2009-03-05
WO2009011889A4 WO2009011889A4 (en) 2009-04-23

Family

ID=40044164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/008745 WO2009011889A2 (en) 2007-07-18 2008-07-16 Compounds and methods for treatment of sickle cell disease or complications associated therewith

Country Status (5)

Country Link
US (2) US8039442B2 (en)
EP (1) EP2173351A2 (en)
CA (1) CA2693590A1 (en)
WO (1) WO2009011889A2 (en)
ZA (1) ZA201000316B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
AU2009257536B2 (en) * 2008-06-13 2015-07-02 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2012047918A1 (en) * 2010-10-04 2012-04-12 Glycomimetics, Inc. Anti-epileptogenic agents
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
HUE045542T2 (en) 2014-12-03 2019-12-30 Glycomimetics Inc Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CA3091454A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
PE20211592A1 (en) 2018-11-29 2021-08-18 Pfizer PIRAZOLES AS HEMOGLOBIN MODULATORS
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
US20070054870A1 (en) * 2005-09-02 2007-03-08 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
DK17885D0 (en) 1985-01-14 1985-01-14 Karlsson Karl Anders ANTIVIRAL AGENT
US4876199A (en) 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US4851511A (en) 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
ATE94395T1 (en) 1986-05-09 1993-10-15 Pulverer Gerhard USE OF SPECIFIC MONOSACCHARIDS FOR THE MANUFACTURE OF A MEDICATION FOR THE PREVENTION OF METASTASIS OF MALIGNANT TUMORS.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US5648344A (en) 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5143712A (en) 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
NZ240646A (en) 1990-11-23 1994-01-26 Gen Hospital Corp Therapeutic interference between cell adhesion proteins and their
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
ATE245696T1 (en) 1991-05-06 2003-08-15 Genentech Inc A SELECTIN LIGAND
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5646123A (en) 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
JPH07507040A (en) 1991-09-10 1995-08-03 セントコー,インコーポレイテッド Peptide inhibitors of selectin-mediated inflammation
US5268364A (en) 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
WO1994004568A1 (en) 1991-12-18 1994-03-03 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US5591835A (en) 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
WO1994005310A1 (en) 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1994006442A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP0601417A3 (en) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
DE69322289T2 (en) 1992-12-29 1999-05-20 Genentech Inc TREATMENT OF INFLAMMABLE INTESTINAL DISEASES WITH INTERFERON GAMMA INHIBITORS
US5412123A (en) 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
CA2157489A1 (en) 1993-03-04 1994-09-15 Masaaki Numata Lewis-associated compound, process for producing the same, and anti-inflammatory
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
CN1125449A (en) 1993-05-14 1996-06-26 萨依特尔有限公司 Sialyl Lex analogues as inhibitors of cellular adhesion
WO1994026786A1 (en) 1993-05-17 1994-11-24 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5750508A (en) 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
WO1995005830A1 (en) 1993-08-20 1995-03-02 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
DE4408248A1 (en) 1994-03-11 1995-09-14 Hoechst Ag Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use
EP0671409A3 (en) 1994-03-11 1996-06-12 Hoechst Ag Malonic acid derivatives having anti-adhesive properties.
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
HUT77345A (en) 1994-04-29 1998-03-30 Texas Biotechnology Corporation Mannopyranosyloxy biphenyl derivatives capable of inhibiting the binding of e-selectin,p-selectin or l-selectin to sialyl-lewis x or sialyl-lewis a and pharmaceutical compositions containing them
US5486536A (en) 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (en) 1994-09-30 1996-04-16 Akira Hasegawa New glycolipid derivative and intermediate for its production
DE4436164A1 (en) 1994-10-10 1996-04-11 Hoechst Ag New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc.
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US20020040008A1 (en) 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (en) 1995-09-06 1997-03-13 Hoechst Ag Novel glycomimetics as selectin antagonists and anti-inflammatory drugs made from them
DE19537334A1 (en) 1995-10-09 1997-04-10 Hoechst Ag New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs.
WO1997015585A1 (en) 1995-10-26 1997-05-01 Kanebo, Ltd. Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
DE19602355A1 (en) 1996-01-24 1997-07-31 Hoechst Ag Multiple fucosylated dicarboxylic acids with anti-adhesive properties
US6169077B1 (en) 1996-01-30 2001-01-02 Glycotech Corp. Sialyl-Lewisa and sialyl-Lewisx epitope analogues
WO1997028174A1 (en) 1996-01-30 1997-08-07 Novartis Ag SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US5962422A (en) 1996-03-01 1999-10-05 The Regents Of The University Of California Inhibition of selectin binding
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
US5994402A (en) 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
US5919768A (en) 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
CA2281684C (en) 1997-02-28 2006-08-29 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (en) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusion protein carrying GALal, 3GAL epitopes
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6037333A (en) 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
US6593459B1 (en) 1998-06-16 2003-07-15 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
WO2000017216A1 (en) 1998-09-21 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Carboxymethylgalactose derivatives
AU773174B2 (en) 1998-11-12 2004-05-20 Novolytics Inc. Compositions and methods for producing vascular occlusion
ATE321570T1 (en) 2000-05-19 2006-04-15 Blood Res Center METHOD FOR TREATING HEMOSTATIC DISORDERS USING SOLUBLE P-SELECTIN
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US20040219158A1 (en) 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US20060287253A1 (en) 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
WO2008100453A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
US20070054870A1 (en) * 2005-09-02 2007-03-08 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMBURY STEPHEN H ET AL: "The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.", BLOOD 15 NOV 2004, vol. 104, no. 10, 15 November 2004 (2004-11-15), pages 3378 - 3385, XP002507353, ISSN: 0006-4971 *
KNEUER ET AL: "Selectins - potential pharmacological targets?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 11, no. 21-22, 18 October 2006 (2006-10-18), pages 1034 - 1040, XP005762277, ISSN: 1359-6446 *
PATTON, J.T. ET AL.: "GMI-1070 : a Small, Glycomimetic, Pan-selectin Antagonist that Improves Blood Flow and Inhibits Blood Cell Adhesion in Sickle Mice", 2 September 2005 (2005-09-02), Glyco XIX, Gaithersburg, Maryland, XP002507352, Retrieved from the Internet <URL:http://www.glycomimetics.com/library/Glyco%2019%20abstract.pdf> [retrieved on 20081208] *
TURHAN ASLIHAN ET AL: "Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 5 MAR 2002, vol. 99, no. 5, 5 March 2002 (2002-03-05), pages 3047 - 3051, XP002507354, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20090023679A1 (en) 2009-01-22
US20120015898A1 (en) 2012-01-19
ZA201000316B (en) 2010-10-27
EP2173351A2 (en) 2010-04-14
WO2009011889A4 (en) 2009-04-23
US8361975B2 (en) 2013-01-29
WO2009011889A2 (en) 2009-01-22
US8039442B2 (en) 2011-10-18
CA2693590A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2009011889A3 (en) Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2008054676A3 (en) Medical devices and methods of using the same
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
WO2007121131A3 (en) Medical devices including shape memory materials
WO2008013893A3 (en) Diagnosis and treatment of age related macular degeneration
WO2008055037A3 (en) Infusion devices and methods
WO2008060788A3 (en) Compositions, methods, and devices for treating liver disease
WO2008034013A3 (en) Medical devices and methods of making the same
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2008103935A3 (en) Novel tobacco compositions and methods of making
WO2008016667A3 (en) Methods to prepare polymer blend implantable medical devices
WO2008091835A3 (en) Implantable medical endoprostheses
EP2197270B8 (en) Placental tissue grafts and improved methods of preparing and using the same
WO2007136790A3 (en) Intracellular kinase inhibitors
IL200939A (en) Prosthesis for reducing injury to soft tissues
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008027600A3 (en) Imatinib compositions
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2011011482A3 (en) Variable density tissue graft composition and methods of making and using the same
WO2008089397A3 (en) Adrb2 cancer markers
WO2007081878A3 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2008066784A3 (en) Expression of foxp3 by cancer cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08794556

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2693590

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 678/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008794556

Country of ref document: EP